Joe Green, Blake Mycoskie
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Commercial investment dominates psychedelic sector funding, primarily for drug discovery. Non-commercial projects need financial backing for drug policy reform, public health education, harm reduction, and diversity initiatives. Strategic funding can
Daniel Goldberg, Andrew Chomer, Lindsay Hoover, Sasha Cohen
Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.
Henry Elkus
United States healthcare faces challenges in accessibility and alignment with patient needs. Leaders discuss patient-centered care and business success in a well-being economy.
Nathan Sackett, Kimberly Roddy, Le Ondra Clark Harvey, Deidra Somerville, Tyler Norris
Visionaries in Colorado and Oregon are shaping new psychedelic eco-systems by teaching, educating, and building businesses and nonprofits. Dreams are becoming reality in these emerging landscapes.
Jamie Beachy, Steve Elfrink, Martha Hammel, Nate Howard, Meaghan Len Richmond, Barine Majewska
International drug policy, historically mirroring US prohibitionist approach, is evolving. Leaders propose regulatory solutions in context of broader drug reform for unified post-prohibition world.
Steve Rolles, Kasia Malinowska
Expansion of psychedelic policy in the US includes decriminalization, adult use regulations, and increased research funding. Elected state lawmakers discuss challenges, opportunities, and lessons from proposed psychedelic legislation.
Rep La Shawn Ford (IL), Rep Alex Dominguez (TX), Tamar Todd
Harm reduction superheroes delve into risk mitigation and benefit maximization, exploring mindset, setting, and substances for safer drug experiences and systemic change.
Mitchell Gomez, Phoenix aka Mohawk Greene
TREAT California initiative aims to transform mental healthcare in California with $5 Billion funding for psychedelic medicine research and access, inspired by successful stem cell agency model.
Jeannie Moller Fontana
Vicky Dulai of Compassion For Addiction moderates a discussion with Amy Emerson of MAPS Public Benefit Corporation and Rachel Yehuda of Icahn School of Medicine on leadership in the psychedelic
Rachel Yehuda
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.